Location History:
- Huddinge, SE (2003)
- Djursholm, SE (2005 - 2008)
Company Filing History:
2 out of 3,539 
1 out of 12 
1 out of 523 
Years Active: 2003-2008
Title: Anne Birgitte Unden: Innovator in Tumor Suppressor Research
Introduction
Anne Birgitte Unden is a prominent inventor based in Djursholm, Sweden. She has made significant contributions to the field of cancer research, particularly in understanding tumor suppressor genes. With a total of 3 patents, her work has implications for the treatment and understanding of various forms of cancer.
Latest Patents
One of her latest patents focuses on the basal cell carcinoma tumor suppressor protein. This invention provides for a tumor suppressor gene inactivation, which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the patched (ptc) gene. Another significant patent relates to a novel human patched-like gene (PTCH2), which has been cloned and sequenced for the first time. Several alternatively spliced mRNA forms of PTCH2 have been identified, including transcripts lacking segments thought to be involved in sonic hedgehog (SHH) binding and mRNAs with differentially defined 3' terminal exons. Furthermore, the invention also relates to the protein encoded by the present PTCH2 as well as to functional analogues and variants thereof.
Career Highlights
Throughout her career, Anne has worked with notable organizations, including the United States of America, as represented by the Secretary, Department of Health and Human Services, and Karolinska Innovations AB. Her research has been pivotal in advancing the understanding of cancer biology and therapeutic approaches.
Collaborations
Anne has collaborated with esteemed colleagues such as Peter G. Zaphiropoulos and Michael C. Dean. Their joint efforts have contributed to the advancement of knowledge in the field of tumor suppressor research.
Conclusion
Anne Birgitte Unden's innovative work in tumor suppressor research has led to significant advancements in understanding cancer mechanisms. Her contributions continue to influence the field and pave the way for future research and therapeutic developments.